BRPI0821266A2 - Derivados de arilamida triazol-substituída e seu uso como anatagonistas de receptores purinérgicos p2x3 e/ou p2x2/3 - Google Patents

Derivados de arilamida triazol-substituída e seu uso como anatagonistas de receptores purinérgicos p2x3 e/ou p2x2/3

Info

Publication number
BRPI0821266A2
BRPI0821266A2 BRPI0821266-0A BRPI0821266A BRPI0821266A2 BR PI0821266 A2 BRPI0821266 A2 BR PI0821266A2 BR PI0821266 A BRPI0821266 A BR PI0821266A BR PI0821266 A2 BRPI0821266 A2 BR PI0821266A2
Authority
BR
Brazil
Prior art keywords
triazol
purinergic receptor
arylamide derivatives
substituted arylamide
receptor anatagonists
Prior art date
Application number
BRPI0821266-0A
Other languages
English (en)
Inventor
Li Chen
Michael Patrick Dillon
Lichun Feng
Ronald Charles Hawley
Minmin Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BR122018070508A priority Critical patent/BR122018070508B8/pt
Publication of BRPI0821266A2 publication Critical patent/BRPI0821266A2/pt
Publication of BRPI0821266B1 publication Critical patent/BRPI0821266B1/pt
Publication of BRPI0821266B8 publication Critical patent/BRPI0821266B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
BRPI0821266A 2007-12-17 2008-12-08 Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica BRPI0821266B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018070508A BR122018070508B8 (pt) 2007-12-17 2008-12-08 derivados de arilamida triazol-substituída e seu uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US789007P 2007-12-17 2007-12-17
PCT/EP2008/066987 WO2009077366A1 (en) 2007-12-17 2008-12-08 Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0821266A2 true BRPI0821266A2 (pt) 2015-06-16
BRPI0821266B1 BRPI0821266B1 (pt) 2019-01-29
BRPI0821266B8 BRPI0821266B8 (pt) 2023-02-07

Family

ID=40383852

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018070508A BR122018070508B8 (pt) 2007-12-17 2008-12-08 derivados de arilamida triazol-substituída e seu uso
BRPI0821266A BRPI0821266B8 (pt) 2007-12-17 2008-12-08 Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018070508A BR122018070508B8 (pt) 2007-12-17 2008-12-08 derivados de arilamida triazol-substituída e seu uso

Country Status (12)

Country Link
US (3) US7989637B2 (pt)
EP (2) EP2225213B1 (pt)
JP (2) JP5318883B2 (pt)
KR (2) KR101284510B1 (pt)
CN (1) CN101903359B (pt)
AU (1) AU2008337660B2 (pt)
BR (2) BR122018070508B8 (pt)
CA (1) CA2707422C (pt)
ES (2) ES2542245T3 (pt)
IL (1) IL205608A (pt)
MX (1) MX2010006230A (pt)
WO (1) WO2009077366A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903362B (zh) * 2007-12-17 2013-07-17 霍夫曼-拉罗奇有限公司 四唑取代的芳基酰胺衍生物和它们作为p2x3和/或p2x2/3嘌呤能受体拮抗物的用途
KR101284510B1 (ko) * 2007-12-17 2013-07-23 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도
CN104058999A (zh) 2008-02-29 2014-09-24 伊沃泰克股份公司 酰胺化合物、组合物及其应用
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
JP5465782B2 (ja) * 2009-06-22 2014-04-09 エフ．ホフマン−ラ ロシュ アーゲー 新規オキサゾロン及びピロリジノン置換アリールアミド
JP5476467B2 (ja) 2009-06-22 2014-04-23 エフ．ホフマン−ラ ロシュ アーゲー 新規なビフェニルピリジンアミドおよびフェニルピリジンアミド
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
UY36422A (es) 2014-12-09 2016-06-30 Evotec Ag Benzamidas sustituidas con 1,3-tiazol-2-ilo
CN107207449B (zh) 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
WO2017060202A1 (en) * 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
AR108222A1 (es) * 2016-05-05 2018-08-01 Elanco Tiergesundheit Ag Compuestos heteroaril-1,2,4-triazol y heteroaril-tetrazol
JP6936257B2 (ja) 2016-05-27 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｅａａｔ３阻害剤としてのピラゾール化合物
CN109563049B (zh) 2016-10-14 2022-11-29 豪夫迈·罗氏有限公司 作为eaat3抑制剂的咪唑化合物
CN112888680A (zh) * 2018-10-19 2021-06-01 先正达参股股份有限公司 杀有害生物活性的唑-酰胺化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6277873B1 (en) 1999-03-25 2001-08-21 Dingwei Tim Yu Oxadiazole antifungal agents
CA2380866A1 (en) 1999-06-30 2001-01-11 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
DE10055713A1 (de) 2000-11-10 2002-05-23 Dingwei Tim Yu Neue Klasse von Antifungimitteln
RS50236B (sr) 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
AP2004003049A0 (en) 2001-11-08 2004-06-30 Elan Pharm Inc N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
WO2003063791A2 (en) 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2003105770A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
RS114004A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
JP2005533852A (ja) 2002-07-18 2005-11-10 セレテック エルエルシー Ｅｄｇ−１受容体に関連した症状の治療方法
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084890A1 (en) 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
US20070060584A1 (en) 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
CA2525437C (en) 2003-05-12 2009-04-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
DK1658302T3 (da) 2003-07-25 2010-11-22 Idenix Pharmaceuticals Inc Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
WO2007020194A1 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Piperidine and piperazine derivatives as p2x3 antagonists
CN103159692B (zh) * 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 四唑取代的芳基酰胺类
EP2091927B1 (en) 2006-11-09 2011-07-20 F. Hoffmann-La Roche AG Thiazole and oxazole-substituted arylamides
AU2008319308B2 (en) * 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
KR101284510B1 (ko) * 2007-12-17 2013-07-23 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도

Also Published As

Publication number Publication date
CA2707422A1 (en) 2009-06-25
KR101284510B1 (ko) 2013-07-23
JP5318883B2 (ja) 2013-10-16
JP5697722B2 (ja) 2015-04-08
CA2707422C (en) 2016-06-07
ES2542245T3 (es) 2015-08-03
BRPI0821266B8 (pt) 2023-02-07
KR101405746B1 (ko) 2014-06-10
EP2607356A1 (en) 2013-06-26
ES2541662T3 (es) 2015-07-23
KR20100083196A (ko) 2010-07-21
IL205608A0 (en) 2010-11-30
CN101903359B (zh) 2013-05-22
KR20130042002A (ko) 2013-04-25
EP2607356B1 (en) 2015-04-29
US20110245271A1 (en) 2011-10-06
AU2008337660A1 (en) 2009-06-25
JP2013231062A (ja) 2013-11-14
BR122018070508B1 (pt) 2019-04-24
BR122018070508B8 (pt) 2021-07-27
EP2225213B1 (en) 2015-04-29
US7989637B2 (en) 2011-08-02
IL205608A (en) 2016-03-31
JP2011506521A (ja) 2011-03-03
BRPI0821266B1 (pt) 2019-01-29
US20090170874A1 (en) 2009-07-02
US20150065521A1 (en) 2015-03-05
MX2010006230A (es) 2010-06-23
US8440708B2 (en) 2013-05-14
WO2009077366A1 (en) 2009-06-25
CN101903359A (zh) 2010-12-01
EP2225213A1 (en) 2010-09-08
AU2008337660B2 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
BRPI0821266A2 (pt) Derivados de arilamida triazol-substituída e seu uso como anatagonistas de receptores purinérgicos p2x3 e/ou p2x2/3
BRPI0815043A2 (pt) mcp-1 mutantes antagonistas de glicosaminoglicanos e métodos para o seu uso
BR112012024870A2 (pt) derivados de 4-aminopirimidina e seus antagonistas do receptor a2a de adenosina
BRPI0814963A2 (pt) Pró-fármacos de dipeptóides e seu uso
BRPI0810523A2 (pt) Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0820838A2 (pt) Derivados de arilamida substituidos por tetrazol e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
BRPI0716936A2 (pt) derivados de adenosina como antigonistas de receptor de a2a
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
ATE481409T1 (de) Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI0813244A2 (pt) Compostos e seus usos 708
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0817685A2 (pt) Polissacarídeos com funcionalidade azetidínio e seus usos
BRPI0807667A2 (pt) Composição emulsificada de óleo-em-água
BRPI0819410A2 (pt) "dispositivo com múltiplas camadas para detecção de analitos"
BRPI0720866A2 (pt) Derivados de oxindol substituídos e seu uso como ligandos de receptor de vasopressina
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0818690A2 (pt) Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0617511A2 (pt) Conjugado de peptídeo-imunoglobulina
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
BRPI0815040A2 (pt) Polímeros emulsificantes e seu uso
BRPI0821244A2 (pt) Proteína de cereal hipoalergênica e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (54) TITULO.